The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 17, 2025

Filed:

May. 12, 2023
Applicants:

Yoshikazu Yonemitsu, Fukuoka, JP;

Gaia Biomedicine Inc., Tokyo, JP;

Inventors:

Yoshikazu Yonemitsu, Fukuoka, JP;

Yui Harada, Fukuoka, JP;

Koji Teraishi, Fukuoka, JP;

Assignees:

Yoshikazu YONEMITSU, Fukuoka, JP;

GAIA BioMedicine Inc., Fukuoka, JP;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/0783 (2010.01); A61K 40/15 (2025.01); A61K 40/42 (2025.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 45/06 (2013.01); A61K 40/15 (2025.01); A61K 40/428 (2025.01); C12N 5/0646 (2013.01); A61K 2239/48 (2023.05); C12N 2500/90 (2013.01); C12N 2501/2302 (2013.01);
Abstract

An NK cell showing higher cytotoxic activity is provided. An object of the present invention is to provide a pharmaceutical composition for NK cell therapies expected to be highly effective. The present invention provides an NK cell having the following characteristics of (1) and (2) or a population thereof: (1) the NK cell is CD16-positive, highly expresses CD56, and is CD57-negative, and (2) the NK cell is NKG2C-positive, is NKG2A-negative or lowly expresses NKG2A, and is CD94-positive. The present invention also provides a pharmaceutical composition containing a population of such NK cells, and a therapeutically effective amount of antibodies.


Find Patent Forward Citations

Loading…